151 related articles for article (PubMed ID: 34127544)
1. Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells.
Fucà G; Ambrosini M; Agnelli L; Brich S; Sgambelluri F; Mortarini R; Pupa SM; Magni M; Devizzi L; Matteucci P; Cabras A; Zappasodi R; De Santis F; Anichini A; De Braud F; Gianni AM; Di Nicola M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34127544
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
Di Nicola M; Zappasodi R; Carlo-Stella C; Mortarini R; Pupa SM; Magni M; Devizzi L; Matteucci P; Baldassari P; Ravagnani F; Cabras A; Anichini A; Gianni AM
Blood; 2009 Jan; 113(1):18-27. PubMed ID: 18809757
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based immunotherapy for the treatment of hematological malignancies.
Büchler T; Michalek J; Kovarova L; Musilova R; Hajek R
Hematology; 2003 Apr; 8(2):97-104. PubMed ID: 12745659
[TBL] [Abstract][Full Text] [Related]
4. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
[TBL] [Abstract][Full Text] [Related]
5. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
6. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.
Curti A; Isidori A; Ferri E; Terragna C; Neyroz P; Cellini C; Ratta M; Baccarani M; Lemoli RM
Leuk Lymphoma; 2004 Jul; 45(7):1419-28. PubMed ID: 15359643
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
9. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
11. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
13. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
Khoury HJ; Collins RH; Blum W; Stiff PS; Elias L; Lebkowski JS; Reddy A; Nishimoto KP; Sen D; Wirth ED; Case CC; DiPersio JF
Cancer; 2017 Aug; 123(16):3061-3072. PubMed ID: 28411378
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
15. Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care.
Bapsy PP; Sharan B; Kumar C; Das RP; Rangarajan B; Jain M; Suresh Attili VS; Subramanian S; Aggarwal S; Srivastava M; Vaid A
Cytotherapy; 2014 Feb; 16(2):234-44. PubMed ID: 24438902
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.
Baek S; Kim YM; Kim SB; Kim CS; Kwon SW; Kim Y; Kim H; Lee H
Cell Mol Immunol; 2015 Jan; 12(1):87-95. PubMed ID: 24976269
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group.
van Gool SW; Holm S; Rachor J; Adamson L; Technau A; Maass E; Frühwald MC; Schlegel PG; Eyrich M
Cytotherapy; 2016 Sep; 18(9):1178-86. PubMed ID: 27421737
[TBL] [Abstract][Full Text] [Related]
18. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]